Clinical Trials IMPACT

The IMPACT trial investigates a very specific and novel immunotherapy called Imotopes™ that has the potential to stop the progression of type 1 diabetes. The treatment is still in its early phase of development but was already administered in a first clinical trial to evaluate its safety. This study is evaluating two doses of Imotope™ in newly diagnosed adult (18-44 years) patients to evaluate efficacy on stopping the loss of the beta cell. Participants will receive 6 initial administrations of the treatment and 1 additional boost administration. Patients will be followed for 1 year.